Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.
Nayak L, Standifer N, Dietrich J, Clarke JL, Dunn GP, Lim M, Cloughesy T, Gan HK, Flagg E, George E, Gaffey S, Hayden J, Holcroft C, Wen PY, Macri M, Park AJ, Ricciardi T, Ryan A, Schwarzenberger P, Venhaus R, Reyes ML, Durham NM, Creasy T, Huang RY, Kaley T, Reardon DA.
Nayak L, et al. Among authors: park aj.
Clin Cancer Res. 2022 Jun 13;28(12):2567-2578. doi: 10.1158/1078-0432.CCR-21-4064.
Clin Cancer Res. 2022.
PMID: 35395080
Free PMC article.
Clinical Trial.